FUNDAMENTALS · Fundamentals · SG Healthcare

HC Surgical Specialists (1B1) Fundamentals 2026 — P/E 6.7x, Revenue Analysis | SniperIQ

HC Surgical Specialists (1B1) is a SG-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of S$61M, trading at S$0.40 on the SES. This SniperIQ fundamentals page covers HC Surgical Specialists's valuation (P/E 6.7x, P/B 2.6x), profitability (net margin 47.2%), revenue (S

9M in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapS$61M
P/E (TTM)6.7x
Net Margin47.2%
Revenue (FY24)S
9M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is HC Surgical Specialists's market cap?

HC Surgical Specialists (1B1) has a market capitalization of approximately S$61M, trading at S$0.40 on the SES. Market cap moves with the live share price.

What is HC Surgical Specialists's P/E ratio?

HC Surgical Specialists's trailing twelve-month P/E ratio is 6.7x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is HC Surgical Specialists?

HC Surgical Specialists runs a net profit margin of 47.2%, a gross margin of 44.3%, and an operating margin of 44.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does HC Surgical Specialists generate?

HC Surgical Specialists reported revenue of S

9M for fiscal year 2024, with net income of S$8M and earnings per share (EPS) of 0.0549. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does HC Surgical Specialists pay a dividend?

HC Surgical Specialists offers a trailing dividend yield of about 5.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is HC Surgical Specialists financially healthy?

HC Surgical Specialists carries a debt-to-equity ratio of 0.10x and a current ratio of 1.96x, with a market beta of -0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is HC Surgical Specialists a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HC Surgical Specialists (1B1) the key facts are: market cap S$61M, P/E 6.7x, revenue S

9M, 52-week range 0.31-0.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track HC Surgical Specialists's full fundamentals live

Get HC Surgical Specialists's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.